Pfizer Skeptical About Value-Based Contracting In Current Environment
Executive Summary
'We have about 18 different projects underway but we've achieved' only one value-based deal, Pfizer CEO Ian Read says. 'The risks and incentives have to be with the providers. … That's how you get the best health care.'
You may also be interested in...
Value-Based Contracting Bill Aims For Bipartisan Political Support
Legislation from Sens. Bill Cassidy and Mark Warner would eliminate barriers to value-based contracting for drugs reimbursed by public payers.
Janssen Emphasizes Average Net Price Decline As Transparency Momentum Builds In States
Rebates, discounts drove Janssen's average net price down 4.6% in 2017 even as average list price increased 8.1%; transparency report emphasizes value-based contracts for prostate cancer, diabetes drugs.
Novartis Begins CAR-T Payment Experiments With Outcomes-Based Contract With CMS
The Centers for Medicare and Medicaid Services will only pay for Kymriah if patients respond after one month. Novartis also pursuing similar contracts with private payers.